Lupus News and Research

Latest Lupus News and Research

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

From CSL Ltd 5 Oct 2009

Membrane-bound Fas ligand is essential for cell death: Researchers

Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also called apoptosis).

1 Oct 2009

National Cancer Institute grants $9.1M award to BUSM

The Black Women's Health Study (BWHS) of the Sloan Epidemiology Center at Boston University School of Medicine's (BUSM) has received a five-year continuation of grant funding award from the National Cancer Institute. The $9.1M award will cover years 16-20 of the largest follow-up study of the health of African-American women.

30 Sep 2009

$4.5 million cost involved for MLSIC set up

The Michigan Economic Development Corp. (MEDC), Ann Arbor SPARK, Greater Wayne Economic Development Corporation and a private foundation have collaborated to create the Michigan Life Science and Innovation Center (MLSIC). MLSIC will connect well-funded, experienced entrepreneurs with business accelerator organizations and start-up life science companies.

25 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

LFA launches new campaign for FDA-approved medication specifically for lupus

It's been 50 years since the U.S. Food and Drug Administration (FDA) approved a medication to treat lupus -- when Dwight D. Eisenhower was President! To highlight the need for safer, more tolerable, and effective medications, the Lupus Foundation of America, Inc. (LFA) today launched its new campaign, Band Together for Lupus(SM), which encourages people to wear an LFA purple wristband until there is a medication approved specifically for lupus by the FDA.

23 Sep 2009

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the premier event hosted by the Society for Vascular Surgery (SVS), was held in mid-June in Denver, Colorado. One physician reported primary patency rates as high as 100 percent for below-knee bypasses.

17 Sep 2009

NIH to fund grants for epigenetic research

The National Institutes of Health announced today that it will fund 22 grants on genome-wide studies of how epigenetic changes -- chemical modifications to genes that result from diet, aging, stress, or environmental exposures -- define and contribute to specific human diseases and biological processes.

17 Sep 2009

New data confirm link between Epstein-Barr virus and multiple sclerosis

Over the last 40 years, Epstein-Barr virus (EBV) has been repeatedly associated with multiple sclerosis and other autoimmune diseases. During the 2nd European Congress of Immunology ECI 2009 held in Berlin, Francesca Aloisi, Istituto Superiore di Sanità, Rome, will present new data that further support the link. In the brain lesions of patients with multiple sclerosis her team found abnormal accumulation of EBV infected B lymphocytes.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

For the second year in a row, BioTrends Research Group, Inc. has been ranked as one of the fastest-growing, privately-held companies in the Philadelphia region by the Philadelphia 100, a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal.

10 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

Lupus Foundation of America takes steps to address shortage of participants for clinical trial

It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus – when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon.

8 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

Lupus Foundation of America to educate people with lupus on clinical trial participation

2 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

Lupus News and Research

Latest Lupus News and Research

Wake Forest University School of Medicine honours researchers

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Schering-Plough receives FDA recommendation approval for PEGINTRON

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Membrane-bound Fas ligand is essential for cell death: Researchers

National Cancer Institute grants $9.1M award to BUSM

$4.5 million cost involved for MLSIC set up

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

LFA launches new campaign for FDA-approved medication specifically for lupus

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

NIH to fund grants for epigenetic research

New data confirm link between Epstein-Barr virus and multiple sclerosis

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

BioTrends Research Group ranked by Philadelphia 100 for the second consecutive time

Merck's GARDASIL receives approval from FDA Advisory Committee

Teva Pharmaceutical Industries to present MS treatment research data

Lupus Foundation of America takes steps to address shortage of participants for clinical trial

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Lupus Foundation of America to educate people with lupus on clinical trial participation

T cells influence aggressive immune cells by regulating the chemical environment between cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Lupus News and Research

Latest Lupus News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in